Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatment

A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC (LSE:TILS, NASDAQ:TLSA, FRA:RTRA, OTC:TIZAF)'s (NASDAQ:TLSA, LON:TILS) monoclonal antibody nasal spray in people with mild-to-moderate Covid. The report in the Frontiers in Immunology showed Foralumab produced a significant reduction in lung inflammation as assessed by a CT scan. Well tolerated by patients, this anti-inflammatory action was “strongly supported” by a drop in serum levels of biomarkers such as Interleukin-6, IL-18 and C-reactive protein. Howard Weiner, a Harvard professor and chairman of the company’s scientific committee, said: “This technology is particularly important, because COVID-19 causes immune hyperactivity, and we believe nasal delivery of Foralumab could rapidly suppress inflammation both in the lung and systemically to provide immediate relief to COVID-19 patients." The update comes ahead of the imminent launch of a phase II, proof-of-concept study of Foralumab, which, like the initial evaluation, will take place in Brazil. It will assess the intranasal drug’s safety, tolerability, and efficacy in a larger number of hospitalised Covid sufferers. Tiziana chief executive, Dr Kunwar Shailubhai, said the clinical findings reported in the article suggested Foralumab in nasal spray form could be developed as a take-home treatment. This, he added, would “circumvent the obstacles associated with intravenous treatments for COVID-19 and its variants”. To read the article in full, click here